ATE496624T1 - Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose - Google Patents

Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose

Info

Publication number
ATE496624T1
ATE496624T1 AT01273650T AT01273650T ATE496624T1 AT E496624 T1 ATE496624 T1 AT E496624T1 AT 01273650 T AT01273650 T AT 01273650T AT 01273650 T AT01273650 T AT 01273650T AT E496624 T1 ATE496624 T1 AT E496624T1
Authority
AT
Austria
Prior art keywords
osteonecrosis
treatment
patients
care
risk
Prior art date
Application number
AT01273650T
Other languages
English (en)
Inventor
David Little
Nicholas Smith
Original Assignee
Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR2907A external-priority patent/AUPR290701A0/en
Priority claimed from AUPR4187A external-priority patent/AUPR418701A0/en
Priority claimed from AUPR6654A external-priority patent/AUPR665401A0/en
Application filed by Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital filed Critical Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital
Application granted granted Critical
Publication of ATE496624T1 publication Critical patent/ATE496624T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01273650T 2001-02-06 2001-12-13 Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose ATE496624T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR2907A AUPR290701A0 (en) 2001-02-06 2001-02-06 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
AUPR4187A AUPR418701A0 (en) 2001-04-03 2001-04-03 A drug for use in bone grafting
AUPR6654A AUPR665401A0 (en) 2001-07-27 2001-07-27 A drug and method for the treatment of osteonecrosis
PCT/AU2001/001616 WO2002062351A1 (en) 2001-02-06 2001-12-13 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis

Publications (1)

Publication Number Publication Date
ATE496624T1 true ATE496624T1 (de) 2011-02-15

Family

ID=27158265

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01273650T ATE496624T1 (de) 2001-02-06 2001-12-13 Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose

Country Status (23)

Country Link
US (2) US7425549B2 (de)
EP (1) EP1365769B1 (de)
JP (1) JP2004527479A (de)
KR (1) KR20030072399A (de)
CN (1) CN1233325C (de)
AT (1) ATE496624T1 (de)
AU (1) AU2002221339B2 (de)
BR (1) BR0116862A (de)
CA (1) CA2435552C (de)
CY (1) CY1111402T1 (de)
CZ (1) CZ301361B6 (de)
DE (1) DE60143964D1 (de)
DK (1) DK1365769T3 (de)
HU (1) HUP0303013A3 (de)
IL (1) IL157201A (de)
MX (1) MXPA03007029A (de)
NO (1) NO20033446L (de)
NZ (1) NZ527351A (de)
PL (1) PL361909A1 (de)
SI (1) SI1365769T1 (de)
SK (1) SK9862003A3 (de)
WO (1) WO2002062351A1 (de)
ZA (1) ZA200305890B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496624T1 (de) * 2001-02-06 2011-02-15 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
AU2002244520B2 (en) * 2001-04-03 2007-05-24 The Royal Alexandra Hospital For Children A drug for use in bone grafting
JP2005514400A (ja) * 2001-12-21 2005-05-19 ザ プロクター アンド ギャンブル カンパニー 骨疾患の治療方法
PT1880744E (pt) * 2002-05-10 2015-02-13 Hoffmann La Roche Ácidos bisfosfónicos para o tratamento e a prevenção da osteoporose
PL212072B1 (pl) * 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
EP1534305B9 (de) 2003-05-07 2007-03-07 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
JPWO2005072747A1 (ja) * 2004-02-02 2007-09-13 小野薬品工業株式会社 骨吸収抑制剤
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
PL1732575T3 (pl) 2004-02-26 2011-05-31 Osteologix As Związki zawierające stron do stosowania w zapobieganiu lub leczeniu stanów nekrotycznych kości
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2006050493A2 (en) * 2004-11-03 2006-05-11 The Regents Of The University Of Michigan Biodegradable implant for intertransverse process fusion
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7833270B2 (en) * 2006-05-05 2010-11-16 Warsaw Orthopedic, Inc Implant depots to deliver growth factors to treat osteoporotic bone
US8062364B1 (en) 2007-04-27 2011-11-22 Knee Creations, Llc Osteoarthritis treatment and device
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PL2459176T3 (pl) 2009-07-31 2018-02-28 Grünenthal GmbH Sposób krystalizacji i biodostępność
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
JP6166471B2 (ja) * 2013-10-25 2017-07-19 アンテシップ バイオベンチャーズ トゥー エルエルシー ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
WO2015200032A1 (en) 2014-06-25 2015-12-30 Spine Wave, Inc. Minimally invasive posterolateral fusion
CN105012995B (zh) * 2015-06-04 2018-03-09 武汉维斯第医用科技股份有限公司 一种含促骨愈合药物的胶原蛋白海绵及其制备方法
WO2016204711A1 (en) 2015-06-16 2016-12-22 Spine Wave, Inc. Instrument and system for placing graft, implant and graft material for minimally invasive posterolateral fusion
WO2017123977A1 (en) * 2016-01-14 2017-07-20 The Regents Of The University Of California Methods of treating osteonecrosis with llp2a-bisphosphonate compounds
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
AU2017204355B2 (en) 2016-07-08 2021-09-09 Mako Surgical Corp. Scaffold for alloprosthetic composite implant

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US5476865A (en) * 1994-07-06 1995-12-19 Eli Lilly And Company Methods of inhibiting bone loss
CN1113440A (zh) 1994-07-29 1995-12-20 孟照强 一种治疗骨伤的中药制剂及其制备方法
WO1996039974A1 (en) * 1995-06-07 1996-12-19 Implex Corporation Femoral head core channel filling prosthesis
US7041641B2 (en) * 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
AU750803B2 (en) 1997-10-29 2002-07-25 University Of Pittsburgh Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
US6268367B1 (en) * 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
JP2002527400A (ja) 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨形成刺激方法
CN1202828C (zh) * 1999-05-21 2005-05-25 诺瓦提斯公司 二膦酸在制备抑制或逆转血管发生的药物中的用途
AUPQ232599A0 (en) 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU781068B2 (en) * 1999-08-19 2005-05-05 Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The Drug for treating fractures
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
ATE496624T1 (de) * 2001-02-06 2011-02-15 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
AUPR553701A0 (en) 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone

Also Published As

Publication number Publication date
CN1529604A (zh) 2004-09-15
CZ301361B6 (cs) 2010-01-27
MXPA03007029A (es) 2004-10-15
ZA200305890B (en) 2005-01-26
PL361909A1 (en) 2004-10-04
US7612050B2 (en) 2009-11-03
CN1233325C (zh) 2005-12-28
EP1365769A1 (de) 2003-12-03
AU2002221339B2 (en) 2006-04-27
EP1365769B1 (de) 2011-01-26
BR0116862A (pt) 2004-01-13
US20090005347A1 (en) 2009-01-01
JP2004527479A (ja) 2004-09-09
SI1365769T1 (sl) 2011-06-30
EP1365769A4 (de) 2005-08-10
WO2002062351A1 (en) 2002-08-15
HK1061797A1 (en) 2004-10-08
CA2435552C (en) 2010-04-27
HUP0303013A3 (en) 2007-06-28
CZ20032408A3 (cs) 2004-06-16
DK1365769T3 (da) 2011-05-16
US7425549B2 (en) 2008-09-16
KR20030072399A (ko) 2003-09-13
CY1111402T1 (el) 2015-08-05
US20040097469A1 (en) 2004-05-20
NO20033446L (no) 2003-10-01
NZ527351A (en) 2005-01-28
CA2435552A1 (en) 2002-08-15
HUP0303013A2 (hu) 2003-12-29
IL157201A (en) 2010-04-29
NO20033446D0 (no) 2003-08-04
DE60143964D1 (de) 2011-03-10
SK9862003A3 (en) 2004-02-03

Similar Documents

Publication Publication Date Title
ATE496624T1 (de) Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
HUP0103182A2 (hu) Dialkil-fumarátok alkalmazása transzplantációs kezelésekben használható gyógyászati készítmények előállítására
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DE69911380D1 (de) Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
ATE358505T1 (de) Beschichtete endovaskuläre vorrichtung
DE602005026078D1 (de) Verwendung von Antioxidantien zur Verhinderung von Oxidation und zur Reduzierung von Wirkstoffzersetzung in wirkstoffhaltigen medizinischen Artikeln
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60235719D1 (de) Frauenhygieneartikel zur verabreichung von arzneimittel
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
DE60204722D1 (de) Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten
SE0303571D0 (sv) Medical product for moisture-sensitive medicaments
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
CY1107095T1 (el) Φαρμακευτικη συνθεση για τοπικη θεραπεια δερματικων παθησεων και τραυματων
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
EP1274423A4 (de) Arzneimittel zur behandlung von traumatischen gehirnschäden und sonstigen neuronalen erkrankungen
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen
PT1235573E (pt) Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1365769

Country of ref document: EP